1-3 of 3
Jason Sit
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Fixed treatment duration mosunetuzumab continues to demonstrate clinically meaningful outcomes in patients with relapsed/refractory (R/R) follicular lymphoma (FL) after ≥2 prior therapies: 5-year follow-up of a pivotal Phase II study

Free
Elizabeth Budde, Laurie Sehn, Matthew Matasar, Stephen Schuster, Sarit Assouline, John Kuruvilla, Won-Seog Kim, Chan Cheah, Mazyar Shadman, Sascha Dietrich, Matthew Ku, Dima El-Sharkawi, Norma Gutiérrez, Michael C. Wei, Shen Yin, Jason Sit, Samuel Tracy, Fidelis Sabalvaro, Elicia Peneul, Nancy Bartlett
Journal: Blood
Blood (2025) 146 (Supplement 1): 5352.
https://doi.org/10.1182/blood-2025-5352
Published: 2025
Journal Articles

Preliminary Findings of a Phase Ib/II Trial Indicate Manageable Safety and Promising Efficacy for Mosunetuzumab in Combination with Lenalidomide (M+Len) in Previously Untreated (1L) Follicular Lymphoma (FL)

Free
Franck Morschhauser, Krish Patel, Sabela Bobillo, Raul Cordoba, Toby A. Eyre, Mark Bishton, Roch Houot, Hui-Lai Zhang, Liqun Zou, Wendy Osborne, Laura Gálvez-Carvajal, Catherine Thieblemont, Donald Yee, Andrea Knapp, Enkhtsetseg Purev, Haocheng Li, Vivian Chen, Karl L. Banta, Jason Sit, Emmanuel Bachy
Journal: Blood
Blood (2023) 142 (Supplement 1): 605.
https://doi.org/10.1182/blood-2023-174432
Published: 2023
Journal Articles

Molecular Determinants of Response to Mosunetuzumab Plus CHOP in Patients with Previously Untreated (1L) Diffuse Large B Cell Lymphoma (DLBCL)

Free
Habib Hamidi, Patrick Kimes, Aaron Schroeder, Jasmina Uzunovic, Adam J Olszewski, Jason Sit, Enkhtsetseg Purev, Donald Yee, Ron McCord
Journal: Blood
Blood (2023) 142 (Supplement 1): 2999.
https://doi.org/10.1182/blood-2023-177591
Published: 2023